Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.

Diabetes Obes Metab. 2023;25:1117-1120

Kolkailah AA, Lingvay I, Dobrecky-Mery I, Aharonovich A, David JP, Holse C, Rasmussen S, McGuire DK